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Polymorphism in active pharmaceutical ingredients can be regarded as critical for the potential that
crystal form can have on the quality, efﬁcacy, and safety of the ﬁnal drug product. The current contri-
bution aims to characterize thermodynamic interrelationship of a dimorphic co-crystal, FI and FII,
involving carbamazepine (CBZ) and saccharin (SAC) molecules. Supramolecular synthesis of CBZ-SAC FI
and FII has been performed using thermokinetic methods and systematically characterized by differ-
ential scanning calorimetry, powder X-ray diffraction, solubility, and slurry measurements. According to
the heat of fusion rule by Burger and Ramberger, FI (DHfus ¼ 121.1 J/g; melting point, 172.5C) and FII
(DHfus ¼ 110.3 J/g; melting point, 164.7C) are monotropically related. The solubility and van't Hoff plot
results suggest FI stable and FII metastable forms. This study reveals that CBZ-SAC co-crystal phases, FI or
FII, could be stable to heat-induced stresses; however, FII converts to FI during solution-mediated
transformation.
© 2017 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Co-crystals1-3 are crystalline entities that comprise more than 1
component in a deﬁned stoichiometric ratio and are held together
by noncovalent interactions. Co-crystals of active pharmaceutical
ingredients (APIs) show great promise in improving pharmaceuti-
cally relevant properties, such as dissolution,4-7 bioavailability,8-11
compressibility,12,13 physical stability,14-17 and photostability.18,19
Thus, pharmaceutical companies are focusing on development as-
pects of co-crystals that include physicochemical characteriza-
tion,20-22 scale-up,23,24 processing, and formulations of these novel
materials.25,26 Polymorphism in APIs is well known and regarded as
critical for the potential that crystal form can have on the quality,
efﬁcacy, and safety of the ﬁnal drug product.27 As an example,
ritonovir, an antiviral drug found to exist in 2 polymorphic forms
(forms I and II), showing signiﬁcantly different bioavailabilities
between these crystalline phases has forced Abbott to change its
formulation.28 In the last 2 decades, there is an increasing interest
in the pharma industry for a thorough evaluation of polymorphs offrom the authors by request
2017.04.017.
44-1274-233900).
radkar).
Inc. on behalf of the American PhaAPIs.29-31 Along the lines, polymorphic behavior of API co-crystals
can inﬂuence the drug development process.32,33 Polymorphism
in co-crystals can be deﬁned as the different co-crystal structures
with the same stoichiometric ratio.34 Initial reports on co-crystals
stated that these materials have fewer tendencies to show poly-
morphism compared with the single-component APIs and salts.
Recent ﬁndings, however, suggest that the difﬁculty in the method
of co-crystal preparation limits the polymorphism in co-crys-
tals.34,35 Jones et al.35 have suggested multiple technique approach
for the co-crystal screening and successfully demonstrated its
application in polymorph screening of phenazine-mesaconic acid
co-crystal. This multiple screening approach includes techniques
such as solution crystallization, crystallization at interface, dry and
liquid-assisted grinding, sublimation, and thermal methods.
Recently, few reports have been published about the preparation of
metastable forms of co-crystal using thermokinetic methods, such
as spray drying36 and rotary evaporation.37 In addition, rapid
heating differential scanning calorimetry (DSC) and controlled
cooling crystallization approaches have showed their potential for
getting co-crystal polymorphs.38
Although new methods have been developed for obtaining co-
crystal polymorphs, there are limited reports on the systematic
evaluation, characterization, and classiﬁcation of the co-crystal
polymorphs. The most important parameter in the characterizationrmacists Association®. This is an open access article under the CC BY license (http://
S.K. Pagire et al. / Journal of Pharmaceutical Sciences 106 (2017) 2009-20142010of polymorphs is the thermodynamic stability relationship between
polymorphic forms.39 Burger and Ramberger40,41 have developed
thermodynamic relationship between the polymorphic forms and
classiﬁed them asmonotropes or enantiotropes based on the heat of
fusion and the melting event of polymorphs. The transition tem-
perature is measured as the temperature where free energy of both
the polymorphs is 0; if the transition temperature falls between 0 K
and melting point of polymorphs, then it is referred to as enantio-
tropes. For monotropic polymorphs, the transition temperature is
either less than 0 K or higher than the melting point of the poly-
morphs. The thermodynamic stability relationship of polymorphs
can be determined from the solubility curves and the van't Hoff plot.
In general, if solubility curves intersect at a temperature below the
meltingpoint, then thepolymorphicpair is enantiotropic,whereas in
the case of monotropic pair, solubility curves would not intersect
between 0 K and the melting point.42 Accordingly, metastable form
can be susceptible to heat or solvent-induced transformation to a
thermodynamically stable crystal form. Therefore, the knowledge of
crystal form stability and their thermodynamic interrelationship is
an important factor for the pharmaceutical processing and formu-
lation development.
The 1:1 co-crystal involving carbamazepine (CBZ) and saccharin
(SAC) is by far one of the most extensively studied pharmaceutical
co-crystal systems (Scheme 1). CBZ-SAC co-crystal exists in 2
polymorphs, form I (FI) and form II (FII). Compared with FI, there
are fewer reports for synthesis and characterization of FII. Matzger
et al.43 have reported the discovery, thermal, and structural char-
acterization of FII. However, the study was not focused on the
thermodynamic interrelationship between FI and FII. Rager and
Hilﬁker44 demonstrated the preparation of CBZ-SAC FI or FII using
solvent mixtures. Recently, Pagire et al.45 have reported the prep-
aration of FII using spherical crystallization technique, and focus of
that work was on the separation of co-crystal forms based on sur-
face energy. Accordingly, the objective of the present contribution
was set out to delineate the thermodynamic relationship of 1:1
CBZ-SAC co-crystal polymorphs (Scheme 1).
Herein, we report the supramolecular synthesis of FI and FII
using thermokinetic methods and a systematic thermodynamic
investigation of interrelationship between FI and FII using solubility
and thermodynamic models.
Experimental
Materials
CBZ and SAC were obtained from Sigma-Aldrich and used as
received. The solvents were of chromatographic grade.
Methods
Preparation of CBZ-SAC Co-Crystal Polymorphs
CBZ-SAC co-crystal forms, FI was prepared using the slow
evaporative solution crystallization method reported by Fleisch-
man et al.,46,47 where CBZ and SAC have been considered in 1:1
molar ratio, and the solvent used for co-crystallizationwas ethanol.
FII was prepared using rotary (fast) evaporation technique, whereScheme 1. Molecular structures of carbamazepine and saccharin.0.557 g of CBZ and SAC in 1:1 stoichiometric ratio was dissolved in
10 mL of solvent mixture consisting of 62.5% methanol and 37.5%
ethanol, respectively. The mixture was heated to 60C to get a clear
solution. Next, it was transferred to a round bottom ﬂask and
concentrated using rotary evaporator. The process parameters
include reduced pressure from 500 to 100 mbar over a period of
5 min, water bath temperature was kept at 60C, and 100 rpm
revolution speed was used. After evaporation of the solvents, vac-
uum was decreased to 50 mbar and held for 10 min to ensure the
removal of residual solvent.
Powder X-ray Diffraction
The X-ray powder diffraction patterns for CBZ-SAC FI and FII
were recorded at a scanning range of 4-40 2q with step size of
0.02 and a 1 s per step time by a Philips automated diffractometer.
Cu Ka radiation was used with a voltage of 40 kV and a current
of 35 mA.
Scanning Electron Microscopy
The morphology of crystal forms was studied using scanning
electron microscopy (SEM). Self-adhesive carbon mounts were
used to mount samples on aluminum pin stubs (Agar Scientiﬁc,
Stansted, UK). SEM images of the mounted samples were collected
using a FEI Quanta 400 scanning electron microscope (Cambridge,
UK) under vacuum and XTM microscope control software, version
2.3.
Differential Scanning Calorimetry
DSC for FI and FII was performed using DSC Q2000 from TA
instruments. Approximately, 2-4 mg of the sample was heated in
the sealed standard aluminum pan from 25 to 200C at heating rate
of 10C/min under nitrogen atmosphere. DSC data were analyzed
using the TA Universal analysis 2000 software, version 4.5A (TA
Instruments, Inc.).
Solubility Curves
The proﬁles were generated based on the solubility of CBZ-SAC
FI and FII in the deionized water at different temperatures ranging
from 10 to 45C. Thermodynamic solubilities of FI and FII were
determined by taking excess of FI or FII aliquot in 2 mL of deionized
water, and stirring was performed. After 6 h, samples were ﬁltered
using syringe ﬁlter (0.45 mM), and ﬁltrate was subjected to solu-
bility analysis. The solubility of FI and FII was measured in terms of
concentration of CBZ using HPLC, and Waters e-2695 equipped
with PDA detector (PDA-2998). The HPLC analysis was performed
using Waters symmetry C18 column with 5 m column packing
material and 4.6  250 mm column dimensions. The HPLC method
used is an isocratic and mobile phase comprising 30% water and
70% acetonitrile containing 0.1% triﬂuroacetic acid as well as ﬂow
rate and injection volume used is 1 mL/min and 10 mL, respectively.
Thermodynamic models (van't Hoff plots) were constructed using
DSC and solubility curves. Accordingly, thermodynamic interrela-
tionship between FI and FII was fully determined.
Lattice Energy Calculations
The lattice energies of CBZ-SAC co-crystal forms, FI and FII, were
performed using the Forcite module in the Materials Studio.48 The
coordinates of single-crystal X-ray diffraction experiments per-
formed at 200 K were minimized by the COMPASS force ﬁeld. The
charges were assigned by the force ﬁeld. The Ewald summation
used to compute the nonbonded interactions that include van der
Waals and electrostatic interactions and the single-point energy
were determined for FI and FII using ﬁne quality convergence.
Finally, lattice energies were computed per molecule based on the
number of molecules present in the unit cell.
Figure 1. SEM images depicting crystal morphologies from (a) slow and (b) rotary evaporative crystallization methods.
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CBZ-SAC co-crystal forms, FI and FII, were prepared using slow
evaporative crystallization and rotary (fast) evaporative methods,
respectively. These were initially characterized using various
analytical techniques, such as SEM, powder X-ray diffraction
(PXRD), and DSC to conﬁrm integrity of a crystal form, and detailed
thermodynamic investigations were carried out.
Physical Characterization
Crystal morphologies obtained either from slow (evaporative)
crystallization or rotary evaporation are provided in Figure 1. The
PXRD patterns determined at ambient conditions (298 K) of these
crystalline materials were compared with simulated powder pat-
terns, which were generated from reported single-crystal X-ray
diffraction data sets of CBZ-SAC co-crystal forms, FI and FII at 200 K
(Fig. 2). The PXRD pattern of slow crystallization product corre-
sponds to that of stable FI, whereas rotary evaporation product
obtained from 62.5% methanol and 37.5% ethanol was in agreement
with that of metastable FII (Fig. 2).40,41 It reveals that PXRD and
simulated patterns match well at low 2q values than at high 2q
values because of temperature difference for data collection of
PXRD (298 K) and simulated patterns (200 K), and such ob-
servations were reported elsewhere for other compounds.49Figure 2. PXRD patterns for CBZ-SAC forms I and II compared with that of respective
simulated powder patterns.In comparison to slow crystallization method, there is relatively
less probability of transformation of metastable to stable form
during rotary evaporation as the solvent is removed rapidly from
the mother liquor.
In rotary evaporation experiments, it was also observed that the
different crystalline forms, such as FII, mixture of FI and FII, were
obtained per solvent composition (SI). This could be due to the
solubility difference of reacting components in a particular solvent
composition led to metastable product phases.
DSC analyses reveals the presence of a single melting endo-
therm for each of the co-crystal phase of CBZ-SAC, FI at 172.45C
and FII at 164.7C, respectively (Fig. 3). These results matched with
that of the literature ﬁndings.43 Accordingly, it conﬁrms the phase
purity of FI and FII (see also SI). A detailed investigation of DSC
traces of FI and FII showed respective single melting endotherm
with a difference of 8C between them. Interestingly, we observed
that DSC proﬁles of FI and FII did not show any solid-solid phase
transitions during heating of phase pure forms. This ﬁnding from
thermal analysis has motivated us for the detailed thermodynamic
investigations to unequivocally ascertain the thermodynamic
interrelationship between FI and FII.Figure 3. DSC proﬁles of CBZ-SAC co-crystal phases, FI and FII.
Figure 4. Variation of energy with temperature for monotropic CBZ-SAC co-crystal
system. Curves HFI, HFII, and HL represent enthalpy, whereas DHf, FI and DHf, FII are
enthalpy of fusion.
Figure 6. van't Hoff plots for CBZ-SAC co-crystal forms, FI and FII. Note the differences
between the slopes of the solubility curves in the plots.
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To understand the stability relationship between the poly-
morphs, it is essential to determine if a given polymorphic system is
enantiotropic or monotropic. The most commonly used method for
estimating thermodynamic relationship between polymorphs is by
means of the heat of fusion rule. According to the heat of fusion rule
by Burger and Ramberger, for the polymorphs, higher melting
polymorph should have higher heat of fusion to relate them
monotropically; otherwise, they are enantiotropic.40,41 In the case
of CBZ-SAC co-crystal polymorphs, heat of fusion values were ob-
tained from DSC analyses, which suggest that FI (DHfus ¼ 121.1 J/g)
and FII (DHfus ¼ 110.3 J/g) are monotropically related.
Accordingly, energy-temperature diagram is constructed based
on the thermodynamic parameters such as heat of fusion and
melting temperature from the DSC analysis (Fig. 4). In general, the
energy-temperature diagram of enantiotropic polymorphs shows
transition temperature between 0 K and lowest melting poly-
morph, whereas monotropic polymorphs show transition temper-
ature above the melting point, which could be an extrapolated
hypothetical transition temperature.40,41 In the present study,
energy-temperature plot suggests that FI and FII aremonotropicallyFigure 5. Solubility versus temperature curves for CBZ-SAC co-crystal phases, FI and FII.related as there is no transition temperature in the practically
acceptable region.
The development of solubility curves in water at different
temperatures and van't Hoff plots are reliable methods to distin-
guish the stability and the thermodynamic relationship of poly-
morphs to understand whether they are enantiotropically or
monotropically related to each other.40 The solubility curves and
van't Hoff plots constructed for FI and FII are shown in Figures 5 and
6 (see SI for the values used for solubility curve and van't Hoff plot).
The solubility curves show the complete solubility dominance of FII
over FI throughout the selected temperature range, and curves are
not intersecting in the measurement area. The results suggest that
FII is a metastable form and FI is a stable form. On the other hand,
van't Hoff plots show the different slopes for the solubility curves of
FI and FII. In general, solubility curves would intersect with each
other at a particular temperature, transition temperature, where
the solubility of both polymorphs is same. Herein, transition tem-
perature has been calculated by extrapolating the van't Hoff plot. In
this study, an extrapolated transition temperature was found to be
464.68 K (191.68C), which is well above the melting temperature
of both the polymorphs, an unrealistic value. Thus, FI and FII
considered as monotropic polymorphs as transition temperature
do not fall within the realistic temperature range.
In an effort to understand the solution-mediated phase trans-
formations of CBZ-SAC dimorphs, FI and FII, slurry state studies
were performed in 3 different solvents; water, ethanol, and meth-
anol at 25C. The slurry containing excess solid of FI or FII was
stirred at 500 rpm. The resulting powders were collected, ﬁltered,
and dried during regular time intervals (30 min, 1 h, 2 h, 4 h, 6 h,
12 h, and 24 h). Analysis of the solids by PXRD revealed that FI
remained intact in 3 of the tested solvents over the period of 24 h,Table 1
Summary of Slurry State Stability of CBZ-SAC Co-Crystal Polymorphs in Water,
Methanol, and Ethanol at 25C Over a Period of 24 h
Solvent Time Intervals
30 min 1 h 2 h 4 h 6 h 12 h 24 h
Slurry of FI
Water FI FI FI FI FI FI FI
Methanol FI FI FI FI FI FI FI
Ethanol FI FI FI FI FI FI FI
Slurry of FII
Water FII FII FII FII FII FII FII
Methanol FI FI FI FI FI FI FI
Ethanol FII FI FI FI FI FI FI
Bold text indicates a form conversion from FII to FI.
Table 2
Physical Properties of CBZ-SAC Co-crystal Forms, FI and FII
Modiﬁcation FI FII
Mp (C) DSC onset temperature 172.5 164.7
Enthalpy of transition/J g1a 121.1 110.3
Calculated density/g cm3a 1.4556 (3) 1.4302 (1)
Packing co-efﬁcient Ck*a 70.2 69.0
Stability Stable Metastable
Lattice energies/kcal mol1a 70.601 68.784
a Determined using the reported single-crystal X-ray diffraction data for FI46 and
FII.43
S.K. Pagire et al. / Journal of Pharmaceutical Sciences 106 (2017) 2009-2014 2013meaning FI is a stable form. However, slurry studies of FII show that
it has converted to FI within 30 min in methanol or within 1 h in
ethanol, meaning FII is a metastable form (Table 1). Notably, FII
intact in water for more than 24 h could be ascribed to the poor
solubility of CBZ-SAC in water at 25C, and also the number of
molecules entered into the liquid phase is too little to form the
nuclei and crystal growth of FI at the tested conditions. The overall
observations suggest that the transformation of the metastable FII
to the stable FI is mediated by the solvent.
The calculated densities, packing fractions, and lattice energies
for FI and FII were also determined using the reported single-crystal
X-ray diffraction data sets (Table 2).48 As per the density rule, the
crystal formwith the greatest density is often the most stable form.
The calculated density of FI was found to be higher than FII, which is
in line with the close packing observed in FI (70.2%) over FII (69%).
The lattice energies further conﬁrm that FI has lower free energy
(~1.82 kcal/mole) compared with FII; accordingly, FI stable and FII
metastable forms.
Conclusions
Polymorphism in molecular crystals involving one-component
systems, such as APIs, has been widely investigated, but limited re-
ports are available on the multicomponent systems such as co-
crystals of APIs and their thermodynamic behavior. In the present
study, we have successfully investigated the thermodynamic sta-
bility and interrelationship between FI and FII of CBZ-SAC co-crystal
using thermal, solubility, and slurry methods. According to the heat
of fusion rule by Burger and Ramberger, FI and FII are monotropically
related. The solubility and van't Hoff plot results conﬁrm that FI is a
stable form and FII is a metastable form, and these are monotropi-
cally related polymorphs. Slurry tests, density rule, and lattice en-
ergy results further conﬁrm the FI stable and FII metastable forms.
This study reveals that there was no phase transformation of FII and
FI during heating. It should be mentioned, however, that FII converts
to FI during solution-mediated transformation, which would
potentially impact formulation development.
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